Opinion|Videos|December 31, 2024
Precision Medicine’s Effect on Atopic Dermatitis Treatment
Author(s)Douglas DiRuggiero, DMSc, MHS, PA-C
A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers
Advertisement
Episodes in this series
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps
3
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
4
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
5